These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 38545115)

  • 1. Therapeutic approaches to enhance natural killer cell cytotoxicity.
    Stenger TD; Miller JS
    Front Immunol; 2024; 15():1356666. PubMed ID: 38545115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
    Jiang D; Zhang J; Mao Z; Shi J; Ma P
    Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
    Fetzko SL; Timothy LD; Parihar R
    Curr Hematol Malig Rep; 2023 Dec; 18(6):264-272. PubMed ID: 37751103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
    Zhang M; Lam KP; Xu S
    Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells in antitumour adoptive cell immunotherapy.
    Laskowski TJ; Biederstädt A; Rezvani K
    Nat Rev Cancer; 2022 Oct; 22(10):557-575. PubMed ID: 35879429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
    Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
    Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the NK cell platform for cancer immunotherapy.
    Myers JA; Miller JS
    Nat Rev Clin Oncol; 2021 Feb; 18(2):85-100. PubMed ID: 32934330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
    Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
    Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cells and cancer therapy, what we know and where we are going.
    Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
    Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
    Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
    Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
    Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
    Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
    Fantini M; Arlen PM; Tsang KY
    Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.